Repetitive Transcranial Magnetic Stimulation for the Treatment of Resistant Depression: A Scoping Review
Open accessThe DOI matches its Crossref record; 77 of the 79 references it cites were found in a registry or an index.
Abstract
Treatment-resistant depression (TRD) is associated with significant disability, and due to its high prevalence, it results in a substantive socio-economic burden at a global level. TRD is the inability to accomplish and/or achieve remission after an adequate trial of antidepressant treatments. Studies comparing repetitive transcranial magnetic stimulation (rTMS) with electroconvulsive therapy (ECT) and pharmacotherapy have revealed evidence of the therapeutic efficacy of rTMS in TRD. These findings suggest a crucial role for rTMS in the management of TRD. This article aims to conduct a comprehensive scoping review of the current literature concerning the use of rTMS and its therapeutic efficacy as a treatment modality for TRD. PubMed, PsycINFO, Medline, Embase, and Cinahl were used to identify important articles on rTMS for TRD. The search strategy was limited to English articles within the last five years of data publication. Articles were included if they reported on a completed randomized controlled trial (RCT) of rTMS intervention for TRD. The exclusion criteria involved studies with rTMS for the treatment of conditions other than TRD, and study and experimental protocols of rTMS on TRD. In total, 17 studies were eligible for inclusion in this review. The search strategy spanned studies published in the last five years, to the date of the data search (14 February 2022). The regional breakdown of the extracted studies was North American (n = 9), European (n = 5), Asian (n = 2) and Australian (n = 1). The applied frequencies of rTMS ranged from 5 Hz to 50 Hz, with stimulation intensities ranging from 80% MT to 120% MT. Overall, 16 out of the 17 studies suggested that rTMS treatment was effective, safe and tolerated in TRD. For patients with TRD, rTMS appears to provide significant benefits through the reduction of depressive symptoms, and while there is progressive evidence in support of the same, more research is needed in order to define standardized protocols of rTMS application in terms of localization, frequency, intensity, and pulse parameters.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Robust evidence (e.g., Wallman et al., 2022;Zis et al., 2020) has demonstrated the safety and tolerability of rTMS and has suggested that it is superior to sham stimulation on variables of depression severity, response, and remission in adults across the lifespan (Adu et al., 2022;De Risio et al., 2020;Gaynes et al., 2014).”
From Neurocognitive effects of theta burst stimulation for treatment-resistant depression in adults: A systematic review and recommendations for future research (2025) · cites this paper as Adu et al., 2022
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Zhao, X., Li, Y., Tian, Q., Zhu, B., & Zhao, Z. (2019) · Journal of International Medical Research · doi:10.1177/0300060518817417 · Cited by 160 · cited 15×
“(2019) [56], elderly depressed patients were randomized into two groups of 29, with one group receiving rTMS and the other as a control group, while another group of 30 healthy volunteers were given rTMS.”
BackgroundMethodInfluentialRetractedRush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630 · cited 1×
“The World Health Organization has recently reported that depression ranks among the leading causes of disability worldwide [64].”
BackgroundNON-INVASIVE MAGNETIC STIMULATION OF HUMAN MOTOR CORTEX
Barker, A. T., Jalinous, R., & Freeston, I. L. (1985) · The Lancet · doi:10.1016/s0140-6736(85)92413-4 · Cited by 4,460
Ferrari, A. J., Charlson, F. J., Norman, R. E., Patten, S. B., Freedman, G., Murray, C. J. L., Vos, T., & Whiteford, H. A. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001547 · Cited by 3,115
A scoping review of scoping reviews: advancing the approach and enhancing the consistency
Pham, M. T., Rajić, A., Greig, J. D., Sargeant, J. M., Papadopoulos, A., & McEwen, S. A. (2014) · Research Synthesis Methods · doi:10.1002/jrsm.1123 · Cited by 3,078
Depression of motor cortex excitability by low-frequency transcranial magnetic stimulation
Chen, R., Classen, J., Gerloff, C., Celnik, P., Wassermann, E. M., Hallett, M., & Cohen, L. G. (1997) · Neurology · doi:10.1212/wnl.48.5.1398 · Cited by 2,128 · cited 1×
“While high-frequency rTMS is deemed to produce a stimulating effect on the cerebral cortex, low-frequency rTMS is believed to have an inhibitory effect [26].”
BackgroundO’Reardon, J. P., Solvason, H. B., Janicak, P. G., Sampson, S., Isenberg, K. E., Nahas, Z., McDonald, W. M., Avery, D., Fitzgerald, P. B., Loo, C., et al. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.01.018 · Cited by 1,910 · cited 3×
“The stimulation of the DLPFC is significantly associated with the enhancement of the neurocognitive domains, and rTMS appears to reduce depressive symptoms, with a subsequent improvement in the neurocognitive functions of TRD patients [30,70,71].”
BackgroundGlobal burden of depressive disorders in the year 2000
Üstün, T. B., Ayuso-Mateos, J. L., Chatterji, S., Mathers, C., & Murray, C. J. L. (2004) · British Journal of Psychiatry · doi:10.1192/bjp.184.5.386 · Cited by 1,735
Risk factors for suicide in individuals with depression: a systematic review
Hawton, K., Casañas i Comabella, C., Haw, C., & Saunders, K. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.01.004 · Cited by 1,469 · cited 1×
“Effective treatment of MDD is available in the form of psychopharmacology, psychotherapy, electroconvulsive therapy (ECT), and other non-invasive brain stimulation methods [5], but affected patients frequently experience relapses and persistent life dysfunction [6], with associated suicidal ideation [7].”
Background
Research works printed but not linked: 2
- Fawcett J. Kravitz H. Treatment refractory depression Common Treat. Probl. Depress. 1985 5 1 27
- Nierenberg A. Keck P. Samson J. Rothschild A. Schatzberg A. Methodological considerations for the study of treatment-resistant depression Adv. Neuropsychiatry Psychopharmacol. 1991 2 83 91
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Effects of chronic stress on cognitive function – From neurobiology to intervention
Girotti, M., Bulin, S. E., & Carreno, F. R. (2024) · Neurobiology of Stress · doi:10.1016/j.ynstr.2024.100670 · Cited by 209
“A recent review evaluating the effectiveness of repetitive TMS (rTMS) to the PFC for TRD concludes that rTMS is reliable, well-tolerated, and efficacious (Adu et al., 2022).”
Postsynaptic Proteins at Excitatory Synapses in the Brain—Relationship with Depressive Disorders
Samojedny, S., Czechowska, E., Pańczyszyn-Trzewik, P., & Sowa-Kućma, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911423 · Cited by 23
Yılmaz, N. S., Şen, B., Karadag, R. F., Aslan, S., Ertek, İ. E., Bozkurt, A., Çiçek, S., Bolu, A., Ucar, H., Koçak, C., et al. (2022) · Journal of Neural Transmission · doi:10.1007/s00702-022-02553-x · Cited by 21
“rTMS is also an important treatment option in this patient group, and its frequency of use is increasing (Fitzgerald 2020; Adu et al. 2022; Baeken and De Raedt 2022; Williams et al. 2021).”
BackgroundWang, Y., Dong, T., Li, X. J., Zhao, H., Yang, L., Xu, R., Fu, Y., Li, L., Gai, X., & Qin, D. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1219590 · Cited by 47
Lucido, M. J., & Dunlop, B. W. (2025) · Brain Sciences · doi:10.3390/brainsci15020161 · Cited by 24
Makale, M. T., Abbasi, S., Nybo, C., Keifer, J., Christman, L. A., Fairchild, J. K., Yesavage, J. A., Blum, K., Gold, M. S., Baron, D. A., et al. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e18943 · Cited by 22
“Interestingly, a recent (2022) retrospective literature meta-analysis of rTMS in depression indicated that a 4–6 week treatment duration yields tangible results, and Carpenter and co-workers (2017) reported that significant antidepressant effects were obtained after 4 weeks of rTMS [102,103].”
BackgroundFaries, E., Mabe, L. A., Franzen, R. L., Murtaza, S., Nathani, K., Ahmed, B., Prokop, L. J., Mohammed, K., & Ahmed, A. T. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.08.212 · Cited by 21
Olivola, M., Mazzoni, F., Tarantino, B., Guffanti, A., Marcatili, M., Macellaro, M., Girone, N., Martiadis, V., Raffone, F., Prodi, T., et al. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1736114 · Cited by 10
Tao, X., Jing, Z. W., Yuan, W. K., Yun, G. H., Fang, X. J., & Sheng, L. M. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1504727 · Cited by 14
Haikazian, S., McIntyre, R. S., Meshkat, S., Kratiuk, K., Llach, C.-D., Orsini, D. K., Luch, S. D. D., & Rosenblat, J. D. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116691 · Cited by 10
“1,2 7 Popular treatment options for treatment-resistant patients include rapid transcranial magnetic stimulation 8 and electroconvulsive therapy 9 , with variable response rates being reported.”
Olivola, M., Mazzoni, F., Tarantino, B., Guffanti, A., Marcatili, M., Motta, F., Cornaggia, R. D., Martiadis, V., Prodi, T., Politi, P., et al. (2025) · Journal of Affective Disorders · doi:10.1016/j.jad.2025.120231 · Cited by 9
Duval, F., Mokrani, M., Dănilă, V., Weiß, T., Lopera, F. G., & Tomsa, M. (2024) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2024.107037 · Cited by 8
Prodi, T., Pezzullo, G., Monica, K. L., Priori, A., Vismara, M. E. M., Dell’Osso, B. M., & Benatti, B. (2024) · Brain Sciences · doi:10.3390/brainsci14090949 · Cited by 11
“By now, the gold standard for TRD remains to be electroconvulsive therapy (ECT), especially in the presence of life-threatening conditions, high suicidal risk, or depression with psychotic symptoms [5].”
Mentalising and depression: a mini-review on behavior, neural substrates, and treatment options
Langenbach, B. P., Koelkebeck, K., & Knoch, D. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1116306 · Cited by 12
Earleywine, M., Oliva, A. B., Leo, J. A. D., & Banks, R. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00265 · Cited by 9
“Authors of a recent scoping review of transcranial magnetic therapy suggest that despite varied results, that approach also shows promise (Adu, Shalaby, Chue, & Agyapong, 2022).”
ResultRobin, A., Thomas-Ollivier, V., Sauvaget, A., Péré, M., & Bulteau, S. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.03.050 · Cited by 4
Physiotherapy for patients with depression: Recent research progress
Liu, H., Sun, J., Meng, S., & Sun, N. (2024) · World Journal of Psychiatry · doi:10.5498/wjp.v14.i5.635 · Cited by 7
Ginelli, E., Sanna, L., Paribello, P., Isayeva, U., Corona, G., Zai, C. C. H., Manca, D., Iaselli, M. N., Collu, R., Pinna, F., et al. (2025) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2025.1584673 · Cited by 8
“Over the past few decades, rTMS has been shown to have a positive impact on depressive symptoms, making it a critical tool for managing TRD cases (5).”
Ikawa, H., Takeda, Y., Osawa, R., Sato, A., Mizuno, H., & Noda, Y. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020399 · Cited by 4
Al-Shamali, H. F., Dong, R., Jackson, M., Burback, L., Wong, G., Cao, B., Li, X., Greenshaw, A. J., & Zhang, Y. (2025) · PLoS ONE · doi:10.1371/journal.pone.0321813 · Cited by 5
Dahrendorff, J., Pages, K. P., Currier, G. W., Sarker, M. H., Graham, Z., Louis‐Jacques, A. F., Dagne, G. A., & Uddin, M. (2025) · BMC Medical Genomics · doi:10.1186/s12920-025-02240-2 · Cited by 4
“In treatment-resistant populations, neuromodulation treatments such as electroconvulsive therapy (ECT), vagus nerve stimulation, and transcranial magnetic stimulation (TMS) are effective alternatives to molec-ular-acting therapies [14–17].”
Hutnyan, M., & McClintock, S. M. (2025) · Transcranial Magnetic Stimulation · doi:10.1016/j.transm.2025.100088 · Cited by 2
Özçelik, Ö., Cinemre, B., Erdogan, A. R., & Metin, Ö. (2023) · SDÜ Tıp Fakültesi Dergisi · doi:10.17343/sdutfd.1256800 · Cited by 1
Al-Shamali, H. F., Janssen‐Aguilar, R., Hussaini, A., Sharma, V., Elugot, H., Li, X., Jetly, R., Zhang, Y., Tang, V. M., Jha, M. K., et al. (2025) · Current Addiction Reports · doi:10.1007/s40429-025-00685-0 · Cited by 2
“…TMS, particularly dTMS, had the most evidence for dual diagnosis populations, especially in cases of AUD and comorbid MDD. TMS is an innovative and well-established intervention, approved by both the Food and Drug Administration (FDA) and Health Canada for treatment-resistant depression (TRD) [41].”
Al-Shamali, H. F., Jackson, M., Zinchuk, N., Modanloo, S., Wong, G., Cao, B., Burback, L., Li, X., Greenshaw, A. J., & Zhang, Y. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1143403 · Cited by 1
Terapijski rezistentna depresija: nove spoznaje u etiopatogenezi i uloga esketamina u liječenju
Medicinski fakultet Sveučilišta u Zagrebu, H., Živković, M., Klinički bolnički centar Zagreb, Z., Žujić, D., Medicinski fakultet Sveučilišta u Zagrebu, H., Mihaljević-Peleš, A., Medicinski fakultet Sveučilišta u Zagrebu, H., & Klinički bolnički centar Zagreb, Z. (2024) · Socijalna psihijatrija · doi:10.24869/spsih.2024.151
“Additionally, non-pharmacological treatment methods such as repetitive transcranial magnetic stimulation (rTMS) and electroconvulsive therapy (ECT), as well as more modern methods like phototherapy (34-36), should also be considered.”
Influential立石, 洋., & 溝口, 義. (2024) · Kyushu Neuropsychiatry · doi:10.11642/kyushuneurop.70.1_3
Alhassan, M. A. (2026) · Annals of General Psychiatry · doi:10.1186/s12991-025-00626-1
“A scoping review of randomized controlled trials (RCTs) conducted across multiple regions, North America (9 studies), Europe (5 studies), Asia (2 studies), and Australia (1 study), revealed that 16 out of 17 studies confirmed the efficacy of rTMS treatment for TRD [67].”
Viegas, C., Ranjbar, S., Mall, J., Vandel, P., von Gunten, A., Moyano, B. P., & Swierkosz-Lenart, K. (2026) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2026.1794892
Noack, K., Gruber, M., Pawlitzki, M., Masanneck, L., Reif-Leonhard, C., Reif, A., Opel, N., Zilles‐Wegner, D., Friedrichson, B., & Repple, J. (2026) · Neuroscience Applied · doi:10.1016/j.nsa.2026.107032
Metadata
- Authors
- Adu, M. K., Shalaby, R., Chue, P., & Agyapong, V. I. O.
- Affiliations
- University of Alberta (CA)
- Dalhousie University (CA)
- Corresponding author
- Adu, Medard Kofi
- Venue
- Behavioral Sciences
- Publisher
- MDPI AG
- Published
- 2022-06-17
- Volume
- 12
- Issue
- 6
- Pages
- 195
- ISSN
- 2076-328X (ISSN-L)
- PMC
- PMC9220129
- OpenAlex
- W4283019182
- Cited by
- 31
- References
- 79
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 10 · 2023: 6 · 2022: 2
- FWCI
- 0.70
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Behavioral Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Mental Health Foundation
- Douglas Harden Trust Fund
- Topics
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- repetitive transcranial magnetic stimulation, treatment-resistant depression, electroconvulsive therapy, antidepressant treatment, randomized controlled trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
